<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03217097</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0284</org_study_id>
    <nct_id>NCT03217097</nct_id>
  </id_info>
  <brief_title>O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents and Interest of Oxaliplatin in Patients With Unmethylated MGMT NET.</brief_title>
  <acronym>MGMT-NET</acronym>
  <official_title>O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents and Interest of Oxaliplatin in Patients With Unmethylated MGMT NET. A Randomized Phase II Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neuroendocrine tumors (NET) are rare but their incidence is growing. Alkylating agents (ALKY)
      are one of the main systemic treatments used, at least for advanced pancreatic NETs, with a
      response rate of 30 to 40% and a median progression-free survival of 4 to 18 months.
      Chemotherapy is one of the few therapeutic weapons, along with everolimus, somatostatin
      analogs, and metabolic radiotherapy, for pulmonary NETs, called typical and atypical
      carcinoids, even if the level of proof of efficacy for these treatments is lower than for
      pancreatic NETs. Considering the available retrospective data, O6-Methylguanine-DNA
      methyltransferase (MGMT) appears to be a predictive factor of the response to ALKY.
      Oxaliplatin (OX) has demonstrated an interesting activity, with response rates between 17%
      and 30%. In a first retrospective study we showed that Gemox is effective in NET, and more
      recently that its activity is similar to that of ALKYs, but without being influenced by the
      MGMT status. Prospective studies are needed but our data suggests that ALKY should be offered
      first to patients with methylated MGMT tumors while Oxaliplatin-based chemotherapy should be
      offered first to patients with unmethylated MGMT tumors. In this project, we wish to evaluate
      the contribution of the MGMT methylation, evaluated in the tumor, in predicting the Objective
      Response (OR) in patients treated with ALKY and to carry out the first randomized phase II
      study comparing a treatment with alkylating agents to Oxaliplatin in patients with a
      pancreatic or broncho-pulmonary NET.

      The main objective of this study is to evaluate the usefulness of tumor MGMT methylation in
      the prediction of the Objective Response (OR) at 3 months in patients treated with ALKY for a
      NET, assessed using the RECIST v1.1 criteria by centralized reading carried out by an expert
      radiologist blinded to the results of the MGMT methylation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response</measure>
    <time_frame>3 months</time_frame>
    <description>Objective Response (OR) at 3 months assessed by RECIST 1.1 criteria based on MGMT methylation in tissue</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Neuroendocrine Carcinomas</condition>
  <arm_group>
    <arm_group_label>Unmethylated MGMT NET - OX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
The &quot;oxaliplatin-based&quot; group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unmethylated MGMT NET - ALKY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with unmethylated MGMT NET will be randomly assigned (1:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
The &quot;alkylating-based&quot; group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylated MGMT NET - OX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
The &quot;oxaliplatin-based&quot; group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methylated MGMT NET - ALKY</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with methylated MGMT NET will be randomly assigned (2:1) to either the alkylating-based chemotherapy arm or to the oxaliplatin-based chemotherapy arm.
The &quot;alkylating-based&quot; group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin-based chemotherapy</intervention_name>
    <description>The &quot;oxaliplatin-based&quot; group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week).</description>
    <arm_group_label>Unmethylated MGMT NET - OX</arm_group_label>
    <arm_group_label>Methylated MGMT NET - OX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alkylating-based chemotherapy</intervention_name>
    <description>The &quot;alkylating-based&quot; group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week).</description>
    <arm_group_label>Unmethylated MGMT NET - ALKY</arm_group_label>
    <arm_group_label>Methylated MGMT NET - ALKY</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years;

          -  Well-differentiated advanced pancreatic and lung NETs (carcinoids);

          -  Patients must have measurable disease using the RECIST 1.1 criteria;

          -  Indication for cytotoxic systemic chemotherapy validated by the dedicated
             multidisciplinary tumor board (RENATEN);

          -  Previous treatments such as surgery, radiofrequency ablation, transarterial liver
             embolization, somatostatin analogs, interferon, everolimus or other targeted therapy,
             and peptide receptor radionuclide treatment (PRRT) are allowed;

          -  MRI (Magnetic Resonance Imaging) or TAP (Thorax, Abdomen and Pelvis) CT scan with
             contrast agents within 4 weeks before inclusion;

          -  Tumor tissue available (fresh frozen or paraffin-embedded) in order to search for the
             methyl guanine methyltransferase (MGMT) status;

          -  Patients with childbearing potential should use effective contraception during the
             study and the following 6 months;

          -  Covered by a Healthcare System where applicable, and/or in compliance with the
             recommendations of the national laws in force relating to biomedical research;

          -  Subject able to understand and willing to sign a written informed consent document;

          -  Signed written informed consent obtained prior to any study-specific screening
             procedures.

        Exclusion Criteria:

          -  Previous chemotherapy using Oxaliplatin or ALKY (streptozotocin, dacarbazine or
             temozolomide). Other chemotherapy (platin-etoposide, folfiri, paclitaxel or docetaxel)
             are allowed;

          -  Pregnant or breastfeeding;

          -  Females of childbearing age potential not using medically accepted contraceptive
             measures, as judged by the investigator;

          -  Contraindication to any drug contained in the chemotherapy regimen;

          -  Any significant disease which, in the investigator's opinion, excludes the patient
             from the study;

          -  Under any administrative or legal supervision.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine LOMBARD BOHAS, MD</last_name>
    <phone>4.72.11.73.98</phone>
    <phone_ext>+33</phone_ext>
    <email>catherine.lombard@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas WALTER, MD</last_name>
    <phone>4.72.11.96.93</phone>
    <phone_ext>+33</phone_ext>
    <email>thomas.walter@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HÃ´pital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine LOMBARD BOHAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Catherine LOMBARD BOHAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas WALTER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic neuroendocrine tumors</keyword>
  <keyword>Broncho-pulmonary neuroendocrine tumors</keyword>
  <keyword>O6-Methylguanine-DNA methyltransferase (MGMT) methylation</keyword>
  <keyword>Alkylating agents</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Streptozocin</mesh_term>
    <mesh_term>Alkylating Agents</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

